BDSX Earnings Prediction
The chart below shows how BDSX performed 10 days before and after its earnings report, based on data from the past quarters. Typically, BDSX sees a +2.25% change in stock price 10 days leading up to the earnings, and a +1.94% change 10 days following the report. On the earnings day itself, the stock moves by -2.71%. This data can give you a slight idea of what to expect for the next quarter's release.
BDSX Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
18.15M
34.54%
1.26%
Gross Margin
76.98%
1.20%
-1.77%
Operating Margin
-47.33%
-10.97%
3.84%
Net Margin
-56.51%
-30.37%
-6.29%
EPS
-0.07
-50.00%
-12.50%
No Data Available
BDSX Earnings Analysis
Biodesix, Inc. Common Stock Corporation (BDSX.O) Earnings Conference Call
Positive
Revenue Growth Surge: 35% year-over-year growth in revenue, reaching $18.2 million in Q3 2024.
Strong Operational Efficiency: 77% gross margins maintained, reflecting strong operational efficiency.
Lung Diagnostic Revenue Surge: Lung diagnostic testing revenue grew 40% year-over-year, driven by increased test volumes and reimbursement successes.
Future Revenue Potential: $11.1 million in contracted but not yet recognized biopharma services revenue, indicating strong future growth potential.
2024 Revenue Guidance Reaffirmed: The company reaffirmed its 2024 total revenue guidance of $70 million to $72 million, demonstrating confidence in continued performance.
Negative
Biopharma Revenue Decline: 1. Decline in Biopharma Services Revenue: Biopharma services revenue decreased by 17% year-over-year, falling to $1.0 million from $1.2 million in Q3 2023, primarily due to delays in sample receipt and project completion.
Rising Operating Expenses: 2. Increased Operating Expenses: Operating expenses rose by 29% year-over-year to $22.6 million, up from $17.4 million in Q3 2023, driven by higher sales and marketing costs and increased depreciation expenses.
Ongoing Financial Challenges: 3. Net Loss Remains Significant: The net loss for Q3 2024 was $10.3 million, only a slight improvement of 6% compared to a net loss of $10.9 million in Q3 2023, indicating ongoing financial challenges.
Cash Position Decrease: 4. Cash Position Decline: Unrestricted cash and cash equivalents decreased to $31.4 million at the end of Q3 2024, down from $42.2 million at the end of Q2 2024, reflecting cash burn and operational expenses.
Revenue Recognition Delay: 5. Delayed Revenue Recognition: The company experienced a delay in revenue recognition due to project timing, with a significant biopharma project shifting from Q3 to Q4, impacting overall revenue expectations.
BDSX FAQs
How does BDSX typically perform around its earnings report dates?
Is Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
BDSX Earning Call Sentiment
Biodesix, Inc. (BDSX) Q3 2024 Earnings Call Transcript
1.0x
00:00
00:00
BDSX.O
-2.47%Positive
The earnings call summary shows a mixed picture: strong revenue growth and improved net loss are positive, but cash position decline and competitive pressures are concerning. The Q&A section highlighted uncertainties in biopharma revenue and unclear management responses, affecting sentiment. The raised revenue guidance and steady gross margins are positive, but the ATM program and regulatory challenges introduce risks. Overall, the sentiment is neutral, as positives are balanced by risks and uncertainties.
